Noninvasive glucose monitor

Last updated
Non-invasive glucose monitor
Purposemeasurement of blood glucose levels

Noninvasive glucose monitoring (NIGM), called Noninvasive continuous glucose monitoring when used as a CGM technique, is the measurement of blood glucose levels, required by people with diabetes to prevent both chronic and acute complications from the disease, without drawing blood, puncturing the skin, or causing pain or trauma. The search for a successful technique began about 1975 and has continued to the present without a clinically or commercially viable product. [1]

Contents

Early history

As of 1999, only one such product had been approved for sale by the FDA, based on a technique for electrically pulling glucose through intact skin, and it was withdrawn after a short time owing to poor performance and occasional damage to the skin of users. [2]

Hundreds of millions of dollars have been invested in companies who have sought the solution to this long-standing problem. Approaches that have been tried include near-infrared spectroscopy (NIRS, measuring glucose through the skin using light of slightly longer wavelengths than the visible region), [3] transdermal measurement (attempting to pull glucose through the skin using either chemicals, electricity or ultrasound), measuring the amount that polarized light is rotated by glucose in the front chamber of the eye (containing the aqueous humor), and many others.

A 2012 study reviewed ten technologies: bioimpedance spectroscopy, microwave/RF sensing, [4] [5] fluorescence technology, mid-infrared spectroscopy, near-infrared spectroscopy, optical coherence tomography, optical polarimetry, Raman spectroscopy, reverse iontophoresis, and ultrasound technology, concluding with the observation that none of these had produced a commercially available, clinically reliable device and that therefore, much work remained to be done. [6]

As of 2014, disregarding the severe shortcomings mentioned above, at least one non-invasive glucose meter was being marketed in a number of countries. [7] [8] Still, as the mean absolute deviation of this device was nearly 30% in clinical trials, "further research efforts were desired to significantly improve the accuracy [...]". [9]

While multiple technologies have been tried, Raman spectroscopy has gained traction as one promising technology for measuring glucose in interstitial fluid. Early attempts include C8 Medisensors [10] and the Laser Biomedical Research Center at Massachusetts Institute of Technology (MIT) which have been working on a Raman spectroscopy sensor for more than 20 years and conducting clinical investigations in collaboration with the Clinical Research Center at University of Missouri, Columbia, US. [11] In 2018 a paper in PLOS ONE showed independent validation data from a clinical investigation comprising 15 subjects with diabetes mellitus type 1 with a mean absolute relative difference (MARD) of 25.8%. [12] The system used, was a custom-built confocal Raman setup. In 2019 researchers at the Samsung Advanced Institute of Technology (SAIT), Samsung Electronics, in collaboration with the Laser Biomedical Research Center MIT developed a new approach based on Raman spectroscopy that allowed them to see the glucose signal directly. The researchers tested the system in pigs and could get accurate glucose readings for up to an hour after initial calibration. [13]

In 2020, German Institute for Diabetes-Technology published data from 15 subjects with type 1 diabetes on a new prototype GlucoBeam based on Raman spectroscopy from RSP Systems Denmark, showing a MARD of 23.6% on independent validation in out-patient setup with up till 8 days without recalibration. [14]

With accuracy on marketed BGM devices in the US between 5.6 and 20.8%. [15] A NIGM solution would likely need to have an accuracy with a MARD below 20% to be widely accepted.

The number of clinical trials of non-invasive glucose monitors has grown throughout the 21st century. While the National Institutes of Health recorded only 4 clinical investigations of the technology from 2000 to 2015, there were 16 from 2016 to 2020. [16]

Wave of new research and development (2020-)

From approximately 2020, onwards there has been increased R&D activity in the space of new NIGM solutions (particularly CGM ones) with renewed focus on approaches that had already been explored, and new ones altogether. [17] This includes both large tech companies, such as Apple and Samsung, and startup companies.

Optical sensing techniques

Optical spectroscopy methods in continuous glucose monitoring (CGM) utilize light to measure glucose levels in the interstitial fluid or blood. These methods typically involve shining a specific wavelength of light (near-infrared, mid-infrared, or Raman) onto the skin, where it interacts with the glucose molecules. The light either gets absorbed or scattered by the glucose, and the resulting changes in the light's properties are detected and analyzed. [18]

Mid-Infrared spectroscopy

DiaMonTech AG is a Berlin, Germany-based privately-held company developing the D-Pocket, [19] a medical device that uses infrared laser technology to scan the tissue fluid in the skin and detect glucose molecules. Short pulses of infrared light are sent to the skin, which are absorbed by the glucose molecules. This generates heat waves that are detected using its patented IRE-PTD method. [20] The company claims a high selectivity of its method, results of a first study have been published in the Journal of Diabetes Science and Technology . In this study, a Median Absolute Relative Difference of 11.3% is claimed. [21] DiaMonTech has announced that its envisioned follow-up product D-Sensor, will feature continuous measurements, making it a CGM though no release date has been given. [22]

Near-Infrared spectroscopy

Apple has been working on a noninvasive CGM combining silicon photonics and optical absorption spectroscopy, [23] that it seeks to integrate into its Apple Watch. In March 2023 it was reported to have established proof-of-concept of a noninvasive CGM. [24] Another company working on noninvasive CGM is Masimo, which sued Apple for patent infringement in this area in 2020. [25] Masimo has also filed new patents through its subsidiary Cercacor (pending as of September 2023) covering a joint continuous glucose monitoring and pump-closed loop delivery system. [26]

U.S. company Rockley Photonics is building a Near-Infrared system. This approach integrates Rockley’s short-wave infrared (SWIR) spectroscopy technology into its miniaturized photonic integrated circuit (PIC) chips, with the resulting mechanism aiming to be embedded into a smartwatch-style wearable device. [27]

Lithuanian company BROLIS is another NIR Spectroscopy emerging NIGM player. [28] Based on news reports, it developed a fully functioning prototype in 2019. [29]

Raman spectroscopy

Samsung announced that it would be incorporating glucose monitoring with its smartwatch with a targeted release year of 2025. It is not clear whether the watch will integrate readings from an external CGM such as Dexcom's or Abbott's, or work standalone. [30] The company in 2020 published literature regarding the aforementioned (see above) non-invasive method it had developed with MIT scientists to engage in continuous glucose monitoring using spectroscopy. [31] The company has filed patents related to this technology. [32] In January 2024, Samsung gave an update affirming its NIGM ambitions but did not give a release date. [33]

Liom (formerly called Spiden) is a Swiss startup building a multi-biomarker and drug level monitoring noninvasive smartwatch wearable (using Raman spectroscopy) with continuous glucose monitoring capability as its first application. [34] [35] It has so far not attained regulatory approval as of October 2023. In January of 2024, Liom declared it had developed a prototype, with a claimed MARD (Mean Absolute Relative Difference) value to a reference glucose measurement of approximately 9%. [36]

Electromagnetic sensing techniques

Electromagnetic sensing for non-invasive glucose monitoring utilizes the interaction between electromagnetic waves and the glucose molecules present in the body. These techniques typically involve applying a specific radio frequency or microwave signal to the skin, which then penetrates the underlying tissues. The presence of glucose alters the dielectric properties (permittivity and conductivity) of the tissue, leading to changes in the amplitude, phase, or other characteristics of the transmitted or reflected electromagnetic waves.

Electrochemical glucose monitoring is based on the glucose oxidation reaction. Glucose oxidase is the enzyme that is specific to glucose. Glucose is oxidized by oxygen in the presence of glucose oxidase and water to make gluconolactone and hydrogen peroxide. Hydrogen peroxide is further oxidized at the electrode, producing free electrons, resulting in an electrical current proportional to the glucose concentration in an area of interest. By measuring this current, the sensor can accurately determine the glucose level. [37]

Radiofrequency-based approaches

Haifa, Israel-based company HAGAR completed a study of its GWave non-invasive CGM, reporting high accuracy. This sensor uses radiofrequency waves to measure glucose levels in the blood. [38] The device had not received regulatory approval anywhere as of August 2023. One of the criticisms of radiofrequency technology as a way of measuring glucose is that studies in 2019 found that glucose can only be detected in the far infrared (nanometer wavelengths), rather than radiofrequencies even in the centimeter and millimeter wavelength range, putting into question the viability of radio frequencies for measuring glucose. [39] A second study (performed in Israel) reported a GWave prototype showed a MARD of 6.7% though Food and Drug Administration (FDA) comparator standards were not applied (the study determined accuracy (MARD) by comparing with a regular Abbott Blood Glucose Monitoring/fingerstick device as a comparator, which measures capillary blood glucose levels, not venous ones as required for FDA CGM approval). [40]

KnowLabs is a Seattle, U.S-based company building a CGM called the Bio-RFID sensor, which works by sending radio waves through the skin to measure molecular signatures in the blood, which Know Labs' machine learning algorithms use to compute the user's blood sugar levels. The company reported that it had built a prototype, but had not attained regulatory approval as of August 2023. [41] In March 2024, news outlets reported that the company's sensor had attained a MARD of 11.1%. [42]

The BioXensor developed by British company BioRX uses patented radio frequency technology, alongside a multiple sensor (also capturing blood oxygen levels, ECG, respiration rate, heart rate and body temperature) approach. [43] The company claims this enables the measurement of blood glucose levels every minute reliably, accurately, and non-invasively. BioXensor had not received regulatory approval as of June 2023.

Afon Technology, based in Wales, is developing Glucowear, a non-invasive continuous glucose monitor (CGM) using radiofrequency (RF) technology. This device, worn under a smartwatch, has the goal to monitor blood glucose in real-time. Their approach uses RF signals to detect glucose levels beneath the skin, differing from optical sensor-based methods. [44]

Synex Medical (based in Boston, US and Toronto, Canada) uses portable magnetic resonance spectroscopy (MRS) for non-invasive glucose monitoring. Their compact devices aim to measure blood metabolites like glucose in real-time by analyzing the magnetic properties of hydrogen atoms in glucose molecules. [45]

Another noninvasive system was attempted to be built by US company Movano Health. It envisioned a small ring placed on the arm. Movano said in 2021 that it was building the smallest ever custom radio frequency (RF)-enabled sensor designed for simultaneous blood pressure and glucose monitoring. [46] Movano is listed as MOVE on NASDAQ. By August 2023 Movano had shifted to building sensor rings for other parameters, such as heart rate, blood oxygen levels, respiration rate, skin temperature variability, and menstrual symptom tracking. [47]

Reverse iontophoresis (Electromagnetic sensing in sweat)

SugarBeat, built by Nemaura Medical, is a wireless non-invasive blood glucose monitoring system using a disposable skin patch. The patch connects to a rechargeable transmitter which detects blood sugar and transfers the data to a mobile app every five minutes. The patch can be used for 24 hours. Electronic currents are used to draw interstitial fluid to the surface to analyse the glucose level. SugarBeat has achieved regulatory approval in Saudi Arabia [48] and Europe, [49] though market penetration rates remain very low. The company declared US$503,906 in revenue for the fiscal year ending March 2022, [50] which compares to Dexcom's more than $3 billion. [51] As of August 2023 it had submitted a US FDA premarket approval application for sugarBEAT. [52] Nemaura was listed on NASDAQ since January 2018 as NMRD. [53] [54] However, due to poor performance (a below than $35m market cap) and low trading volumes it was threatened with delisting from NASDAQ (in April 2023). [55] It was delisted from NASDAQ January 4, 2024 and is currently trading on OTC. [56]

Magnetohydrodynamic approaches

Glucomodicum is based in Helsinki, Finland and was founded as a spin out of the University of Helsinki. Their attempted solution uses interstitial fluid to non-invasively measure glucose levels continuously. It does not have regulatory approval. [57] Its device is a combination of magnetohydrodynamic (MHD) technology, advanced algorithms and highly-sensitive biosensors which link to a smartphone app for data collection and reporting. It works by sending a small amount of energy through the skin to the interstitial fluid between the cells, bringing the fluid to the surface of the skin for non-invasive sample capture. [58]

Eye scanning

Occuity, a Reading, UK-based startup is taking a different approach to noninvasive glucose monitoring, by using the eye. [59] The company states it is developing the Occuity Indigo, [60] which aims to measure the change in refractive index of the eye to determine the concentration of glucose in the blood. [61]

Breath analysis

BOYDSense is a French-based startup developing a noninvasive glucose monitoring device that analyzes breath-based volatile organic compounds (VOCs). The company’s device, Lassie, measures specific VOCs in the breath, which are metabolic byproducts of glucose usage in the body. Early clinical trials have demonstrated that these VOCs can reliably indicate blood glucose levels in individuals with type 2 diabetes. BOYDSense’s goal is to provide a compact, affordable alternative to traditional CGMs, which rely on blood samples. The technology is currently in clinical trials, with ongoing research to refine its accuracy and algorithm. [62]

Related Research Articles

<span class="mw-page-title-main">Insulin pump</span> Medical device to administer insulin

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy. The device configuration may vary depending on design. A traditional pump includes:

<span class="mw-page-title-main">Blood glucose monitoring</span> Use of a glucose monitor for testing the concentration of glucose in the blood

Blood glucose monitoring is the use of a glucose meter for testing the concentration of glucose in the blood (glycemia). Particularly important in diabetes management, a blood glucose test is typically performed by piercing the skin to draw blood, then applying the blood to a chemically active disposable 'test-strip'. The other main option is continuous glucose monitoring (CGM). Different manufacturers use different technology, but most systems measure an electrical characteristic and use this to determine the glucose level in the blood. Skin-prick methods measure capillary blood glucose, whereas CGM correlates interstitial fluid glucose level to blood glucose level. Measurements may occur after fasting or at random nonfasting intervals, each of which informs diagnosis or monitoring in different ways.

<span class="mw-page-title-main">Blood sugar level</span> Concentration of glucose present in the blood (Glycaemia)

The blood sugar level, blood sugar concentration, blood glucose level, or glycemia is the measure of glucose concentrated in the blood. The body tightly regulates blood glucose levels as a part of metabolic homeostasis.

<span class="mw-page-title-main">Pulse oximetry</span> Measurement of blood oxygen saturation

Pulse oximetry is a noninvasive method for monitoring blood oxygen saturation. Peripheral oxygen saturation (SpO2) readings are typically within 2% accuracy of the more accurate reading of arterial oxygen saturation (SaO2) from arterial blood gas analysis.

Glycated hemoglobin, glycohemoglobin, glycosylated hemoglobin is a form of hemoglobin (Hb) that is chemically linked to a sugar. Several types of glycated hemoglobin measures exist, of which HbA1c, or simply A1c, is a standard single test. Most monosaccharides, including glucose, galactose, and fructose, spontaneously bond with hemoglobin when present in the bloodstream. However, glucose is only 21% as likely to do so as galactose and 13% as likely to do so as fructose, which may explain why glucose is used as the primary metabolic fuel in humans.

<span class="mw-page-title-main">Glucose meter</span> Medical device for determining the concentration of glucose in the blood

A glucose meter, also referred to as a "glucometer", is a medical device for determining the approximate concentration of glucose in the blood. It can also be a strip of glucose paper dipped into a substance and measured to the glucose chart. It is a key element of glucose testing, including home blood glucose monitoring (HBGM) performed by people with diabetes mellitus or hypoglycemia. A small drop of blood, obtained from slightly piercing a fingertip with a lancet, is placed on a disposable test strip that the meter reads and uses to calculate the blood glucose level. The meter then displays the level in units of mg/dL or mmol/L.

<span class="mw-page-title-main">Nanoprobe (device)</span>

A nanoprobe is an optical device developed by tapering an optical fiber to a tip measuring 100 nm = 1000 angstroms wide.

<span class="mw-page-title-main">Automated insulin delivery system</span>

Automated insulin delivery systems are automated systems designed to assist people with insulin-requiring diabetes, by automatically adjusting insulin delivery in response to blood glucose levels. Currently available systems can only deliver a single hormone—insulin. Other systems currently in development aim to improve on current systems by adding one or more additional hormones that can be delivered as needed, providing something closer to the endocrine functionality of the pancreas.

<span class="mw-page-title-main">Masimo</span> American health technology company

Masimo Corporation is a health technology and consumer electronics company based in Irvine, California. The company primarily manufactures patient monitoring devices and technologies, including non-invasive sensors using optical technology, patient management, and telehealth platforms. In 2022, the company expanded into home audio by acquiring Sound United, and began to manufacture health-oriented wearable devices.

<span class="mw-page-title-main">Minimed Paradigm</span> Insulin pumps

MiniMed Paradigm is a series of insulin pumps manufactured by Medtronic for patients with diabetes mellitus. The pump operates with a single AAA battery and uses a piston-plunger pump to infuse a programmed amount of insulin into the patient through a length of tubing. The Paradigm uses a one-way wireless radio frequency link to receive blood sugar measurements from select glucose meters. The Paradigm RT series adds the ability to receive data from a mated continuous blood-glucose monitor. Although the pump can use these measurements to assist in calculating a dose of insulin, no actual change in insulin delivery occurs without manual user-intervention.

DexCom, Inc. is a company that develops, manufactures, produces, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has manufacturing facilities in Mesa, Arizona and Batu Kawan, Malaysia.

Fluorescent glucose biosensors are devices that measure the concentration of glucose in diabetic patients by means of sensitive protein that relays the concentration by means of fluorescence, an alternative to amperometric sension of glucose. Due to the prevalence of diabetes, it is the prime drive in the construction of fluorescent biosensors. A recent development has been approved by the FDA allowing a new continuous glucose monitoring system called EverSense, which is a 90-day glucose monitor using fluorescent biosensors.

<span class="mw-page-title-main">Monitoring (medicine)</span> Observation of a disease, condition or one or several medical parameters over time

In medicine, monitoring is the observation of a disease, condition or one or several medical parameters over time.

Continuous noninvasive arterial pressure (CNAP) is the method of measuring beat-to-beat arterial blood pressure in real-time without any interruptions (continuously) and without cannulating the human body (noninvasive).

Google Contact Lens was a smart contact lens project announced by Google on 16 January 2014. The project aimed to assist people with diabetes by constantly measuring the glucose levels in their tears. The project was being carried out by Verily and as of 2014 was being tested using prototypes. On November 16, 2018, Verily announced it had discontinued the project.

Ambulatory glucose profile (AGP) is a single-page, standardized report for interpreting a patient's daily glucose and insulin patterns. AGP provides both graphic and quantitative characterizations of daily glucose patterns. First developed by Drs. Roger Mazze and David Rodbard, with colleagues at the Albert Einstein College of Medicine in 1987, AGP was initially used for the representation of episodic self-monitored blood glucose (SMBG). The first version included a glucose median and inter-quartile ranges graphed as a 24-hour day. Dr. Mazze brought the original AGP to the International Diabetes Center (IDC) in the late 1980s. Since then, IDC has built the AGP into the internationally recognized standard for glucose pattern reporting.

GlySens, a biomedical technology company, is a privately owned corporation developing a long term internal continuous glucose monitor in order to effectively manage and observe glucose levels in real time. The GlySens ICGM system is the world's first surgically implanted continuous glucose monitoring system to demonstrate an 18-month performance in a preclinical setting. GlySens Incorporated was founded in 1998 by David A. Gough and Joseph Lucisano, a bioengineering graduate at the University of California, San Diego. The implanted continuous glucose monitoring system uses an internal sensor equipped with electrochemical detectors to measure glucose readings via a chemical reaction between enzymes and oxygen.

<span class="mw-page-title-main">Continuous glucose monitor</span> Blood glucose monitoring device

A continuous glucose monitor (CGM) is a device used for monitoring blood glucose on a continual basis instead of monitoring glucose levels periodically by drawing a drop of blood from a finger. This is known as continuous glucose monitoring. CGMs are used by people who treat their diabetes with insulin, for example people with type 1 diabetes, type 2 diabetes, or other types of diabetes, such as gestational diabetes.

Bioinstrumentation or Biomedical Instrumentation is an application of biomedical engineering which focuses on development of devices and mechanics used to measure, evaluate, and treat biological systems. The goal of biomedical instrumentation focuses on the use of multiple sensors to monitor physiological characteristics of a human or animal for diagnostic and disease treatment purposes. Such instrumentation originated as a necessity to constantly monitor vital signs of Astronauts during NASA's Mercury, Gemini, and Apollo missions.

Nemaura Medical Inc. is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBeAT.

References

  1. ↑ The Pursuit of Noninvasive Glucose, 7th Edition, by John L. Smith, Ph.D.
  2. ↑ Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO (November 1999). "Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team". JAMA. 282 (19): 1839–44. doi:10.1001/jama.282.19.1839. PMID   10573275.
  3. ↑ Ahmad M, Kamboh A, Khan A (16 October 2013). "Non-invasive blood glucose monitoring using near-infrared spectroscopy". EDN Network.
  4. ↑ Huang SY, Yoshida Y, Inda AJ, Xavier CX, Mu WC, Meng YS, Yu W (October 2018). "Microstrip line-based glucose sensor for noninvasive continuous monitoring using the main field for sensing and multivariable crosschecking". IEEE Sensors Journal. 19 (2): 535–47. Bibcode:2019ISenJ..19..535H. doi:10.1109/JSEN.2018.2877691. S2CID   56719208.
  5. ↑ Yu W, Huang SY (October 2018). "T-Shaped Patterned Microstrip Line for Noninvasive Continuous Glucose Sensing". IEEE Microwave and Wireless Components Letters. 28 (10): 942–4. doi:10.1109/LMWC.2018.2861565. S2CID   52932653.
  6. ↑ So CF, Choi KS, Wong TK, Chung JW (June 29, 2012). "Recent advances in noninvasive glucose monitoring". Medical Devices: Evidence and Research. 5: 45–52. doi: 10.2147/MDER.S28134 . PMC   3500977 . PMID   23166457.
  7. ↑ "Distributors | GlucoTrack".
  8. ↑ "Cnoga Medical".
  9. ↑ Vashist SK (October 2013). "Continuous Glucose Monitoring Systems: A Review". Diagnostics. 3 (4): 385–412. doi: 10.3390/diagnostics3040385 . PMC   4665529 . PMID   26824930.
  10. ↑ Lipson J, Bernhardt J, Block U, Freeman WR, Hofmeister R, Hristakeva M, et al. (March 2009). "Requirements for calibration in noninvasive glucose monitoring by Raman spectroscopy". Journal of Diabetes Science and Technology. 3 (2): 233–41. doi:10.1177/193229680900300203. PMC   2771519 . PMID   20144354.
  11. ↑ Singh SP, Mukherjee S, Galindo LH, So PT, Dasari RR, Khan UZ, et al. (October 2018). "Evaluation of accuracy dependence of Raman spectroscopic models on the ratio of calibration and validation points for non-invasive glucose sensing". Analytical and Bioanalytical Chemistry. 410 (25): 6469–6475. doi:10.1007/s00216-018-1244-y. PMC   6128756 . PMID   30046865.
  12. ↑ Lundsgaard-Nielsen SM, Pors A, Banke SO, Henriksen JE, Hepp DK, Weber A (2018). "Critical-depth Raman spectroscopy enables home-use non-invasive glucose monitoring". PLOS ONE. 13 (5): e0197134. Bibcode:2018PLoSO..1397134L. doi: 10.1371/journal.pone.0197134 . PMC   5947912 . PMID   29750797.
  13. ↑ Kang JW, Park YS, Chang H, Lee W, Singh SP, Choi W, et al. (January 2020). "Direct observation of glucose fingerprint using in vivo Raman spectroscopy". Science Advances. 6 (4): eaay5206. Bibcode:2020SciA....6.5206K. doi: 10.1126/sciadv.aay5206 . PMC   6981082 . PMID   32042901.
  14. ↑ Pleus S, Schauer S, Jendrike N, Zschornack E, Link M, Hepp KD, et al. (August 2020). "Proof of Concept for a New Raman-Based Prototype for Noninvasive Glucose Monitoring". Journal of Diabetes Science and Technology. 15 (1): 11–18. doi:10.1177/1932296820947112. PMC   7783007 . PMID   32783466.
  15. ↑ Ekhlaspour L, Mondesir D, Lautsch N, Balliro C, Hillard M, Magyar K, et al. (May 2017). "Comparative Accuracy of 17 Point-of-Care Glucose Meters". Journal of Diabetes Science and Technology. 11 (3): 558–566. doi:10.1177/1932296816672237. PMC   5505415 . PMID   27697848.
  16. ↑ "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-08-28.
  17. ↑ Harb, Frédéric; Azar, William S.; Ghadieh, Hilda E.; Njeim, Rachel; Tawk, Youssef; Costantine, Joseph; Kanj, Rouwaida; Eid, Assaad A. (2022), "Future Developments in Invasive and Non-invasive Diabetes Monitoring", Springer Series on Bio- and Neurosystems, Cham: Springer International Publishing, pp. 293–313, doi:10.1007/978-3-030-99728-1_15, ISBN   978-3-030-99727-4 , retrieved 2024-06-28
  18. ↑ Di Filippo, Daria; Sunstrum, Frédérique N.; Khan, Jawairia U.; Welsh, Alec W. (2023-11-12). "Non-Invasive Glucose Sensing Technologies and Products: A Comprehensive Review for Researchers and Clinicians". Sensors (Basel, Switzerland). 23 (22): 9130. Bibcode:2023Senso..23.9130D. doi: 10.3390/s23229130 . ISSN   1424-8220. PMC   10674292 . PMID   38005523.
  19. ↑ "D-Pocket - Non-Invasive Glucose Monitoring". DiaMonTech.
  20. ↑ "DiaMonTech Develops Non-invasive Blood Glucose Monitor That Uses M-IR Lasers". www.ophiropt.com. n.d. Retrieved 2023-08-30.
  21. ↑ Lubinski, Thorsten; Plotka, Bartosz; Janik, Sergius; Canini, Luca; Mäntele, Werner (2020-07-05). "Evaluation of a Novel Noninvasive Blood Glucose Monitor Based on Mid-Infrared Quantum Cascade Laser Technology and Photothermal Detection". Journal of Diabetes Science and Technology. 15 (1): 6–10. doi:10.1177/1932296820936634. ISSN   1932-2968. PMC   7780361 . PMID   32627580.
  22. ↑ O’Neill, Simon (April 2022). "Update on technologies, medicines and treatments". Diabetic Medicine. 39 (4). doi:10.1111/dme.14800. ISSN   0742-3071.
  23. ↑ Park, Andrea (23 February 2023). "Apple's long-desired glucose tracking is reportedly at proof-of-concept stage: Bloomberg". Fierce Biotech. Retrieved 28 June 2024.
  24. ↑ Park, Andrea (February 23, 2023). "Apple's long-desired glucose tracking is reportedly at proof-of-concept stage: Bloomberg". FierceBiotech. Retrieved September 14, 2023.
  25. ↑ Smith, Niel (2021-03-17). "Masimo's approach to noninvasive blood glucose monitoring and its fight with Apple". MyHealthyApple. Retrieved 2023-09-17.
  26. ↑ US20230226331A1,Kiani, Massi Joe E.; Pauley, Kevin Hughes& Vo, Hung Theet al.,"Modular wearable device for patient monitoring and drug administration",issued 2023-07-20
  27. ↑ "Rockley Photonics Advances Non-Invasive Blood Glucose Monitoring". Yahoo Finance. 2023-09-26. Retrieved 2024-06-29.
  28. ↑ Di Filippo, Daria; Sunstrum, Frédérique N.; Khan, Jawairia U.; Welsh, Alec W. (2023-11-12). "Non-Invasive Glucose Sensing Technologies and Products: A Comprehensive Review for Researchers and Clinicians". Sensors (Basel, Switzerland). 23 (22): 9130. Bibcode:2023Senso..23.9130D. doi: 10.3390/s23229130 . ISSN   1424-8220. PMC   10674292 . PMID   38005523.
  29. ↑ "Brolis develops laser sensor for non-invasive blood analysis - News". Compound Semiconductor. Retrieved 2024-06-29.
  30. ↑ "Samsung's next-gen display to add blood pressure and sugar level monitoring". nextpit. 2022-12-05. Retrieved 2023-10-10.
  31. ↑ "Samsung Researchers' Non-Invasive Blood Glucose Monitoring Method Featured in 'Science Advances'". Samsung. 2020-01-29.
  32. ↑ US11617523B2,Lee, So Young; Kim, Sang Kyu& Bae, Sang Konet al.,"Apparatus and method for estimating biological component",issued 2023-04-04
  33. ↑ "Samsung Races Apple to Develop Blood Sugar Monitor That Doesn't Break Skin". www.bloomberg.com. Retrieved 2024-06-28.
  34. ↑ "Say goodbye to needles for blood glucose monitoring". swisstech. 2024-04-03. Retrieved 2024-09-24.
  35. ↑ "Swiss-based Longevity-focused Startup Spiden Raises $18 Million to Expand Its Light+AI-based Real-time Blood Diagnostics Platform". www.businesswire.com. 2021-04-29. Retrieved 2023-10-28.
  36. ↑ "Spiden Announces Breakthrough in Non-Invasive Glucose Monitoring, Adds Key Executive Hires and Secures $15m in Additional Funding". www.newswire.com (Press release). Retrieved 2024-04-15.
  37. ↑ Ahmed, Israr; Jiang, Nan; Shao, Xinge; Elsherif, Mohamed; Alam, Fahad; Salih, Ahmed; Butt, Haider; K. Yetisen, Ali (2022). "Recent advances in optical sensors for continuous glucose monitoring". Sensors & Diagnostics. 1 (6): 1098–1125. doi: 10.1039/D1SD00030F .
  38. ↑ Barbella, Michael (12 May 2023). "HAGAR Releases Preliminary Study Results for its Non-Invasive Glucose Monitoring System". Medical Product Outsourcing.
  39. ↑ Yilmaz, Tuba; Foster, Robert; Hao, Yang (2019-01-08). "Radio-Frequency and Microwave Techniques for Non-Invasive Measurement of Blood Glucose Levels". Diagnostics. 9 (1): 6. doi: 10.3390/diagnostics9010006 . ISSN   2075-4418. PMC   6468903 . PMID   30626128.
  40. ↑ Hirsch, Irl B.; Tirosh, Amir; Navon, Ami (2024-05-17). "Noninvasive Real-Time Glucose Monitoring Is in the Near Future". Diabetes Technology & Therapeutics. doi:10.1089/dia.2024.0009. ISSN   1520-9156. PMID   38417015.
  41. ↑ Park, Andreas (Jun 28, 2023). "Know Labs unveils first prototype of portable, noninvasive glucose monitor". FierceBiotech.
  42. ↑ "Know Labs' Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study". Yahoo Finance. 2024-03-06. Retrieved 2024-06-29.
  43. ↑ Seitz, Sara (20 June 2023). "GlucoRX BioXensor Raises Bar For Multi-Sensor Devices" . Retrieved August 29, 2023.
  44. ↑ "EUROPEAN INNOVATION COUNCIL AND SMES EXECUTIVE AGENCY - No more pricks: Afon's non-invasive glucose sensor to launch in 2024 (Gadgets & Wearables | United Kingdom)". ec.europa.eu. Retrieved 2024-09-23.
  45. ↑ "Researchers use magnetic fields for non-invasive blood glucose monitoring". Engadget. 2023-11-16. Retrieved 2024-09-23.
  46. ↑ "Movano's upcoming health ring could eventually offer non-invasive blood pressure and glucose monitoring". TechSpot. 2021-12-27. Retrieved 2023-08-30.
  47. ↑ "Movano Health Submits FDA Application for Evie Ring, Its Clinical-Grade Wearable for Women" . Retrieved 2023-08-30.
  48. ↑ "Nemaura Medical Announces SFDA Approval of sugarBEAT". BioSpace (Press release). 2023-08-17.
  49. ↑ Kirsh, Danielle (30 May 2019). "Nemaura Medical wins CE Mark for SugarBeat CGM". Drug Delivery Business.
  50. ↑ "Nemaura Medical Reports Financial Results and Provides Business Update for the Fiscal Year Ended March 31, 2022". GlobeNewswire News Room (Press release). 30 June 2022.
  51. ↑ "Dexcom lifts revenue forecast on demand for glucose-monitoring devices". Reuters. 2023-07-27. Retrieved 2023-08-30.
  52. ↑ "Nemaura Medical Announces SFDA Approval of sugarBEAT" (Press release). Bloomberg. 2023-08-17.
  53. ↑ "Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018" . Retrieved 2018-05-26.
  54. ↑ "Bashir Timol from Nemaura Medical speaking at NASDAQ Closing Bell Ringing Ceremony". NASDAQ 2018-03-06. Retrieved 2018-06-18.
  55. ↑ MarketScreener (2023-04-07). "NEMAURA MEDICAL INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)". MarketScreener. Retrieved 2023-09-10.
  56. ↑ "MIAX Exchange Group - Options Markets - Delisting of Nemaura Medical Inc. (NMRD) | MIAX". www.miaxglobal.com. Retrieved 2024-01-11.
  57. ↑ Salmivaara, Kati; Lautala, Elisa (8 November 2019). "GlucoModicum: Needle-free and painless health monitoring". www.helsinki.fi (Press release). University of Helsinki.
  58. ↑ Philpott, Jenna (2024-06-17). "GlucoModicum ups manufacturing after positive data for needle-free CGM". Medical Device Network. Retrieved 2024-06-28.
  59. ↑ "What is Oculomics? The eye as a window on the health of the body". Occuity. Retrieved 2024-01-10.
  60. ↑ "Occuity Indigo - Non-Invasive Glucose Monitor". Occuity. Retrieved 2024-01-10.
  61. ↑ Fernández, Clara Rodríguez (2022-10-07). "Needle-free diabetes care: 7 devices that painlessly monitor blood sugar". Labiotech.eu. Retrieved 2024-01-10.
  62. ↑ Helwig, Collin (2024-04-17). "BoydSense Raises $7.5M for Breathable Glucose Monitor". Athletech News. Retrieved 2024-09-24.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.